主页 > 医学动态 >
【drug-news】意大利研究人员研制了新型潜在镇痛
Public release date: 16-Mar-2007
Potential new pain killer drug developed by scientists at Leicester and Italy
A potential new pain-killing drug developed by medical scientists at the University of Leicester and Ferrara in Italy is to be discussed at a public lecture on 20th March.
Professor David Lambert, who has been involved in the development the drug in collaboration with Dr Girolamo Calo in Ferrara Italy, believes the new drug ?called UFP-101 - avoids many of the side effects of morphine, currently the 慻old standard?in pain reduction.
He said: "In a 2005 survey for the British Pain Society 975 people were questioned about pain. Twenty one percent experienced pain every day or most days equating to ~10million across the whole UK.
"Morphine produces its clinical effects by interaction with opioid receptors. In addition to acting as a pain killer this drug produces a number of unwanted side effects of importance from a clinical (e.g., depression of breathing, constipation and tolerance) and social (addiction) viewpoints.
"Clearly there is a place for new morphine like drugs without these side effects and the University of Leicester Anaesthesia Division has been at the forefront of such preclinical research."
Since appointment in 1991 as a lecturer Professor Lambert has been working on opioids and opioid receptors with particular emphasis on understanding receptor function and the design and evaluation of new drugs to target these receptors.
In collaboration with Dr Girolamo Calo his laboratory has characterised a prototype analgesic (pain killer), acting at a new opioid receptor, with a much reduced side effect profile.
In his inaugural lecture he will describe the current place of opioids in the clinic and development of UFP-101. 本人认领此文。如在48小时内未能提交译文，其他战友可自由认领。 Potential new pain killer drug developed by scientists at Leicester and Italy
A potential new pain-killing drug developed by medical scientists at the University of Leicester and Ferrara in Italy is to be discussed at a public lecture on 20th March.
莱切斯特和意大利的科学家们研制了新型潜在镇痛药
莱切斯特大学和意大利的Ferrara大学的医学科学家们研制了一种新型潜在镇痛药，3月20日的一个公开报告会上将对这种药进行讨论。
Professor David Lambert, who has been involved in the development the drug in collaboration with Dr Girolamo Calo in Ferrara Italy, believes the new drug ?called UFP-101 - avoids many of the side effects of morphine, currently the 慻old standard?in pain reduction.
在此药研制过程中和意大利Ferrara的Girolamo Calo 博士合作的David Lambert教授相信这种名为UFP-101新药没有吗啡所具有的许多副作用，按照现在依据的老标准？在止痛作用上。
He said: "In a 2005 survey for the British Pain Society 975 people were questioned about pain. Twenty one percent experienced pain every day or most days equating to ~10million across the whole UK.
他说：“在2005年对英国疼痛协会的975人的关于疼痛的文娟调查中.每天或基本每天都感觉疼痛的人占了21％，相当于整个英国每年有约1000万这类人。”
"Morphine produces its clinical effects by interaction with opioid receptors. In addition to acting as a pain killer this drug produces a number of unwanted side effects of importance from a clinical (e.g., depression of breathing, constipation and tolerance) and social (addiction) viewpoints.
“吗啡通过与阿片受体作用而发挥其临床效用.除了作为止痛药的作用外，这种药产生许多临床（比如：呼吸抑制，便秘和耐受）和社会（成瘾）意义上不希望发生的副作用”
"Clearly there is a place for new morphine like drugs without these side effects and the University of Leicester Anaesthesia Division has been at the forefront of such preclinical research."
“很明显不具有这些副作用的新型吗啡能够有一席之地，莱切斯特大学的麻醉分会已经在这个药的临床前研究中走在了前面”
Since appointment in 1991 as a lecturer Professor Lambert has been working on opioids and opioid receptors with particular emphasis on understanding receptor function and the design and evaluation of new drugs to target these receptors.
自从1991年成为讲师后，Lambert教授一直致力于阿片类和阿片受体的研究，特别是弄清受体功能的研究，并且致力于针对这些受体的新药的设计和评价。
In collaboration with Dr Girolamo Calo his laboratory has characterised a prototype analgesic (pain killer), acting at a new opioid receptor, with a much reduced side effect profile.
同Girolamo博士合作，他的实验室已经得到了作用于新阿片受体的原型止痛（镇痛）药，这种药的副作用大大降低。
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-01-30 05:14
医学,生命科学网